In addition, we found that GSK-J4 treatment led to significantly prolonged survival and reduced leukemia burden in mice xenografted with AML patient-derived xenograft (PDX) #1 cells (ASXL1 G646WfsX12) without reducing body weight (Figure 7J and Supplemental Figure 7, N–Q). This evidence concerns the gene ASXL1 and acute myeloid leukemia.